2w60 › Citations

Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis.

Figure 1.
Figure 2.
Figure 3.
Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engström A, Serre G, Burkhardt H, Thunnissen MM, Holmdahl R
OpenAccess logo J Exp Med 206 449-62 (2009)
Cited: 153 times
EuropePMC logo PMID: 19204106

Abstract

Antibodies to citrulline-modified proteins have a high diagnostic value in rheumatoid arthritis (RA). However, their biological role in disease development is still unclear. To obtain insight into this question, a panel of mouse monoclonal antibodies was generated against a major triple helical collagen type II (CII) epitope (position 359-369; ARGLTGRPGDA) with or without arginines modified by citrullination. These antibodies bind cartilage and synovial tissue, and mediate arthritis in mice. Detection of citrullinated CII from RA patients' synovial fluid demonstrates that cartilage-derived CII is indeed citrullinated in vivo. The structure determination of a Fab fragment of one of these antibodies in complex with a citrullinated peptide showed a surprising beta-turn conformation of the peptide and provided information on citrulline recognition. Based on these findings, we propose that autoimmunity to CII, leading to the production of antibodies specific for both native and citrullinated CII, is an important pathogenic factor in the development of RA.

Articles - 2w60 mentioned but not cited (3)

  1. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engström A, Serre G, Burkhardt H, Thunnissen MM, Holmdahl R. J Exp Med 206 449-462 (2009)
  2. Improved prediction of antibody VL-VH orientation. Marze NA, Lyskov S, Gray JJ. Protein Eng Des Sel 29 409-418 (2016)
  3. Accurate Structure Prediction of CDR H3 Loops Enabled by a Novel Structure-Based C-Terminal Constraint. Weitzner BD, Gray JJ. J Immunol 198 505-515 (2017)


Reviews citing this publication (58)

  1. Rheumatoid arthritis. Scott DL, Wolfe F, Huizinga TW. Lancet 376 1094-1108 (2010)
  2. Nonresolving inflammation. Nathan C, Ding A. Cell 140 871-882 (2010)
  3. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmström V, Feldmann M, Venables PJ. Immunol Rev 233 34-54 (2010)
  4. Anti-CCP antibodies: the past, the present and the future. van Venrooij WJ, van Beers JJ, Pruijn GJ. Nat Rev Rheumatol 7 391-398 (2011)
  5. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. Suurmond J, Diamond B. J Clin Invest 125 2194-2202 (2015)
  6. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Klareskog L, Malmström V, Lundberg K, Padyukov L, Alfredsson L. Semin Immunol 23 92-98 (2011)
  7. The influence of ACPA status and characteristics on the course of RA. Willemze A, Trouw LA, Toes RE, Huizinga TW. Nat Rev Rheumatol 8 144-152 (2012)
  8. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Arend WP, Firestein GS. Nat Rev Rheumatol 8 573-586 (2012)
  9. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Catrina AI, Ytterberg AJ, Reynisdottir G, Malmström V, Klareskog L. Nat Rev Rheumatol 10 645-653 (2014)
  10. Genetics of rheumatoid arthritis: what have we learned? Bax M, van Heemst J, Huizinga TW, Toes RE. Immunogenetics 63 459-466 (2011)
  11. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Deane KD, Norris JM, Holers VM. Rheum Dis Clin North Am 36 213-241 (2010)
  12. Developments in the scientific understanding of rheumatoid arthritis. Goronzy JJ, Weyand CM. Arthritis Res Ther 11 249 (2009)
  13. Mechanisms involved in triggering rheumatoid arthritis. Catrina AI, Joshua V, Klareskog L, Malmström V. Immunol Rev 269 162-174 (2016)
  14. Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Holmdahl R, Malmström V, Burkhardt H. Eur J Immunol 44 1593-1599 (2014)
  15. Complement in the Initiation and Evolution of Rheumatoid Arthritis. Holers VM, Banda NK. Front Immunol 9 1057 (2018)
  16. NETosis as Source of Autoantigens in Rheumatoid Arthritis. Corsiero E, Pratesi F, Prediletto E, Bombardieri M, Migliorini P. Front Immunol 7 485 (2016)
  17. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Sakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD. Autoimmun Rev 13 1114-1120 (2014)
  18. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maśliński W. Cent Eur J Immunol 42 390-398 (2017)
  19. Rheumatoid arthritis: a role for immunosenescence? Lindstrom TM, Robinson WH. J Am Geriatr Soc 58 1565-1575 (2010)
  20. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Uysal H, Nandakumar KS, Kessel C, Haag S, Carlsen S, Burkhardt H, Holmdahl R. Immunol Rev 233 9-33 (2010)
  21. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. Tan EM, Smolen JS. J Exp Med 213 1937-1950 (2016)
  22. Arthritis models: usefulness and interpretation. Bessis N, Decker P, Assier E, Semerano L, Boissier MC. Semin Immunopathol 39 469-486 (2017)
  23. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, Vital E, Nissim A, Winyard PG, Emery P, Ponchel F. Mediators Inflamm 2014 492873 (2014)
  24. Lessons from animal models of arthritis over the past decade. van den Berg WB. Arthritis Res Ther 11 250 (2009)
  25. Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. Koning F, Thomas R, Rossjohn J, Toes RE. Nat Rev Rheumatol 11 450-461 (2015)
  26. Role of Macrophages in Cardioprotection. Yap J, Cabrera-Fuentes HA, Irei J, Hausenloy DJ, Boisvert WA. Int J Mol Sci 20 E2474 (2019)
  27. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Holers VM. Curr Opin Immunol 25 728-735 (2013)
  28. Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis. Klareskog L, Amara K, Malmström V. Curr Opin Rheumatol 26 72-79 (2014)
  29. Antibody-dependent and -independent mechanisms of inflammatory arthritis. Chang MH, Nigrovic PA. JCI Insight 4 125278 (2019)
  30. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Modi S, Soejima M, Levesque MC. Clin Exp Immunol 173 8-17 (2013)
  31. To B or not to B the conductor of rheumatoid arthritis orchestra. Moura RA, Graca L, Fonseca JE. Clin Rev Allergy Immunol 43 281-291 (2012)
  32. From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. Scherer HU, van der Woude D, Toes REM. Nat Rev Rheumatol 18 371-383 (2022)
  33. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. Catrina A, Krishnamurthy A, Rethi B. RMD Open 7 e001228 (2021)
  34. Pathogenic antibody recognition of cartilage. Nandakumar KS. Cell Tissue Res 339 213-220 (2010)
  35. Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool. Moeez S, John P, Bhatti A. Rheumatol Int 33 1669-1673 (2013)
  36. Autoantibody Biomarkers in Rheumatic Diseases. Kang EH, Ha YJ, Lee YJ. Int J Mol Sci 21 E1382 (2020)
  37. The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Bax M, Huizinga TW, Toes RE. Semin Immunopathol 36 313-325 (2014)
  38. Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders. Weissert R. Front Immunol 8 336 (2017)
  39. Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. Nandakumar KS. Int J Mol Sci 19 E677 (2018)
  40. Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis. Hanyecz A, Olasz K, Tarjanyi O, Nemeth P, Mikecz K, Glant TT, Boldizsar F. Biomed Res Int 2014 942148 (2014)
  41. Epitope Specificity of Anti-Citrullinated Protein Antibodies. Trier NH, Houen G. Antibodies (Basel) 6 E5 (2017)
  42. Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis. Maseda D, Bonami RH, Crofford LJ. Expert Rev Clin Immunol 10 747-762 (2014)
  43. Update on autoantibodies to modified proteins. Toes RE, Huizinga TJ. Curr Opin Rheumatol 27 262-267 (2015)
  44. Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics. Meehan RT, Amigues IA, Knight V. Diagnostics (Basel) 11 1362 (2021)
  45. Aberrant Activation of Immune and Non-Immune Cells Contributes to Joint Inflammation and Bone Degradation in Rheumatoid Arthritis. Nandakumar KS, Fang Q, Wingbro Ågren I, Bejmo ZF. Int J Mol Sci 24 15883 (2023)
  46. Antibody Cross-Reactivity in Auto-Immune Diseases. Trier NH, Houen G. Int J Mol Sci 24 13609 (2023)
  47. Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: a reflection of the involvement of transglutaminase in coeliac disease. Stenberg P, Roth B, Wollheim FA. Eur J Intern Med 20 749-755 (2009)
  48. Interaction between Mesenchymal Stem Cells and the Immune System in Rheumatoid Arthritis. Bačenková D, Trebuňová M, Morochovič R, Dosedla E, Findrik Balogová A, Gašparová P, Živčák J. Pharmaceuticals (Basel) 15 941 (2022)
  49. Disease mechanisms in preclinical rheumatoid arthritis: A narrative review. Romão VC, Fonseca JE. Front Med (Lausanne) 9 689711 (2022)
  50. Immunomodulation in human and experimental arthritis: including vitamin D, helminths and heat-shock proteins. Ishikawa LL, Shoenfeld Y, Sartori A. Lupus 23 577-587 (2014)
  51. Redox-Mediated Carbamylation As a Hapten Model Applied to the Origin of Antibodies to Modified Proteins in Rheumatoid Arthritis. Trejo-Zambrano MI, Gómez-Bañuelos E, Andrade F. Antioxid Redox Signal 36 389-409 (2022)
  52. Autoimmunity: break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. Kroese FG, Baeten D, Huizinga TW. Immunol Lett 162 150-162 (2014)
  53. Targeting mechanisms at sites of complement activation for imaging and therapy. Holers VM. Immunobiology 221 726-732 (2016)
  54. Insights from populations at risk for the future development of classified rheumatoid arthritis. Holers VM. Rheum Dis Clin North Am 40 605-620 (2014)
  55. Mechanisms of assembly and remodelling of the extracellular matrix. Naba A. Nat Rev Mol Cell Biol (2024)
  56. Significance of Type II Collagen Posttranslational Modifications: From Autoantigenesis to Improved Diagnosis and Treatment of Rheumatoid Arthritis. Batsalova T, Dzhambazov B. Int J Mol Sci 24 9884 (2023)
  57. The peculiar features, diversity and impact of citrulline-reactive autoantibodies. Raposo B, Klareskog L, Robinson WH, Malmström V, Grönwall C. Nat Rev Rheumatol 20 399-416 (2024)
  58. [New era of laboratory testing. Topics: II. Particulars; 7. Recent topics in rheumatology]. Sawada T. Nihon Naika Gakkai Zasshi 102 3154-3159 (2013)

Articles citing this publication (92)



Quick links